Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Wright Reports
|
$472.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Wuhan National Pharmaceutical Technology Co Ltd Announces FY 2012 Net Profit Outlook
Wuhan National Pharmaceutical Technology Co Ltd announced that it expects its net profit for fiscal year (FY) 2012 to be RMB 113 million to RMB 120 million, compared to the net profit of FY 2011 (RMB -20,173,311.53). The Company cited the land compensation and subsidies it received as the main reasons for the forecast.
Latest Developments for Wuhan National Pharmaceutical Technology Co Ltd
- Share this
- Link this
- Digg this
Follow Reuters